Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study

Eslamparast, Tannaz; Poustchi, Hossein; Zamani, Farhad; Sharafkhah, Maryam; Malekzadeh, Reza; Hekmatdoost, Azita

doi:10.3945/ajcn.113.068890

Cited by 322 publications

(215 citation statements)

References 26 publications

Supporting

Mentioning

201

Contrasting

Unclassified

Order By: Relevance

“…Additionally, they showed that synbiotic supplementation attenuates inflammatory markers and decreases BMI and waistto-hip ratio that was evident at week 14 and sustained until the end of the treatment (23). Similar results were found by Malaguarnera et al (24) in a study on adults; Bifidobacterium longum with fructooligosaccharide and lifestyle modification for 24 weeks significantly reduces steatosis and the non-alcoholic steatohepatitis (NASH) activity index when compared to lifestyle modification alone.…”

Section: Discussionsupporting

confidence: 73%

Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease

Çakır¹,

İşbilen²,

Eyüpoglu³

et al. 2017

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims:We aimed to analyze the efficiency of a novel treatment approach, long-term synbiotic supplementation, in addition to lifestyle changes in children with non-alcoholic fatty liver disease (NAFLD). Materials and Methods: The study included children with NAFLD (n=28) and a healthy control group (n=30). Children with NAFLD were given 1 capsule/day of synbiotics. Anthropometric parameters; biochemical analysis, including ethanol, tumor necrosis factor-α (TNF-α), total oxidant status (TOS) and anti-oxidant status (TAS), zonulin, and fecal calprotectin; and ultrasonographic examination were performed at baseline and 4 months later. Results: The grade of fatty liver was decreased (≥1 grade) in 19 of the 28 patients (67.8%) after synbiotic supplementation. Total cholesterol, low-density lipoprotein (LDL) levels, TNF-α, C-reactive protein (CRP), and ethanol were significantly decreased, and TAS levels were significantly increased at the end of treatment (p<0.05 for all). We found that the median decrease in CRP (-0.16 vs. -0.03 mg/dL, p=0.003) and LDL levels (-17 vs. -3 mg/dL, p=0.019) were higher in patients who responded to the supplementation.

show abstract

Section: Discussionsupporting

confidence: 73%

Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease

Çakır¹,

İşbilen²,

Eyüpoglu³

et al. 2017

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The importance of the gut microbiome in the prevention and treatment of NAFLD is highlighted by the fact that fecal transplantation from mice with NAFLD into wild-type mice caused NAFLD in mice that received the microbiota (25). In addition, the alteration of microbiota can change the disease severity (26)(27)(28)(29)(30). Overall, these results suggest that the microbiome is important in NAFLD.…”

Section: Introductionmentioning

confidence: 64%

Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet

Mokhtari

Gibson

Hekmatdoost

2017

Advances in Nutrition

Self Cite

132

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder in the world, yet the pathogenesis of the disease is not well elucidated. Due to the close anatomic and functional association between the intestinal lumen and the liver through the portal system, it is speculated that the gut microbiome may play a pivotal role in the pathogenesis of NAFLD. Furthermore, diet, which can modulate the gut microbiome and several metabolic pathways involved in NAFLD development, shows a potential tripartite relation between the gut, diet, and the liver. In this review, we summarize the current evidence that supports the association between NAFLD, the gut microbiome, and the role of diet. Adv Nutr 2017;8:240-52.

show abstract

“…The results showed that synbiotic therapy significantly decreased ALT levels compared to that in placebo group [141]. Malaguarnera et al revealed that therapy with synbiotic ( B. longum and Fos) and lifestyle intervention in NASH patients produced much more improvement compared lifestyle intervention alone including reduction of serum TNFα, CRP, endotoxin and AST levels, improvement in HOMA-IR and extent of NASH activity index [142].…”

Section: Gut Microbiota-targeted Therapy With Symbioticmentioning

confidence: 95%

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Ma¹,

Zhou²,

Li³

2017

Preprint

View full text Add to dashboard Cite

Gut microbiota play critical roles in development of obese-related metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, and insulin resistance, which highlighted the potential of gut microbiota-targeted therapies on these diseases. There are various ways that can manipulate gut microbiota including probiotics, prebiotics, synbiotics, antibiotics and some active components from herbal medicines. In this review, we first described the main roles of gut microbiota in mediating the development of NAFLD, and the advances in gut microbiota-targeted therapies in NAFLD in both the experimental and clinical studies, as well as the conclusions on the prospect of gut microbiotatargeted therapies in the future.

show abstract

Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study

Cited by 322 publications

References 26 publications

Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease

Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease

Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Contact Info

Product

Resources

About